2B30 Stock Chart & Stats
€7.09
-€0.08(-1.17%)
At close: 4:00 PM EDT
€7.09
-€0.08(-1.17%)
Day’s Range― - ―
52-Week Range€4.38 - €8.48
Previous CloseN/A
Volume0.00
Average Volume (3M)207.00
Market Cap
€1.26B
Enterprise Value€1.18K
Total Cash (Recent Filing)€111.75M
Total Debt (Recent Filing)€37.33M
Price to Earnings (P/E)114.1
Beta1.17
Next Earnings
Aug 06, 2026EPS Estimate
0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.07
Shares Outstanding172,642,060
10 Day Avg. Volume412
30 Day Avg. Volume207
Financial Highlights & Ratios
PEG Ratio-22.22
Price to Book (P/B)92.00
Price to Sales (P/S)4.32
P/FCF Ratio45.09
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€10.77Price Target Upside51.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.13
Revenue Forecast (FY)€338.09M
Bulls Say, Bears Say
Bulls Say
Commercial DiversificationAnalyst cites commercial momentum across the product portfolio, with multiple products showing revenue growth and an expanding patient base that could diversify revenue sources.
Profitability And MarginsAnalyst expects expanding gross margins, improving operating leverage, and a self-sustaining balance sheet to support profitability while the company funds commercial expansion and pipeline development.
ValuationAnalyst notes the stock trades at a valuation discount to peers despite consistent commercial execution, implying potential for a market re-rating as investor focus shifts to fundamentals.
Bears Say
Growth Sustainability And Regulatory RiskAnalyst raises concern about whether the main drug's growth drivers can be sustained and warns that regulatory setbacks for a related product could undermine long-term revenue forecasts.
Visibility And VolatilityAnalyst highlights limited visibility into prescription trends between reporting periods, creating stock volatility and making interim company updates especially influential on valuation.
Xeris Pharmaceuticals News
2B30 FAQ
What was Xeris Pharmaceuticals’s price range in the past 12 months?
Xeris Pharmaceuticals lowest stock price was €4.38 and its highest was €8.47 in the past 12 months.
What is Xeris Pharmaceuticals’s market cap?
Xeris Pharmaceuticals’s market cap is €1.26B.
When is Xeris Pharmaceuticals’s upcoming earnings report date?
Xeris Pharmaceuticals’s upcoming earnings report date is Aug 06, 2026 which is in 4 days.
How were Xeris Pharmaceuticals’s earnings last quarter?
Xeris Pharmaceuticals released its earnings results on May 07, 2026. The company reported €0.009 earnings per share for the quarter, beating the consensus estimate of -€0.003 by €0.011.
Is Xeris Pharmaceuticals overvalued?
According to Wall Street analysts Xeris Pharmaceuticals’s price is currently Undervalued.
Does Xeris Pharmaceuticals pay dividends?
Xeris Pharmaceuticals does not currently pay dividends.
What is Xeris Pharmaceuticals’s EPS estimate?
Xeris Pharmaceuticals’s EPS estimate is 0.01.
How many shares outstanding does Xeris Pharmaceuticals have?
Xeris Pharmaceuticals has 172,642,060 shares outstanding.
What happened to Xeris Pharmaceuticals’s price movement after its last earnings report?
Xeris Pharmaceuticals reported an EPS of €0.009 in its last earnings report, beating expectations of -€0.003. Following the earnings report the stock price went up 2.224%.
Which hedge fund is a major shareholder of Xeris Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:2B30
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Xeris Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€10.77 (51.88% Upside)
€10.77 (51.88% Upside)
Blogger Sentiment
Bullish
DE:2B30 Sentiment 75%
Sector Average 65%
Sector Average 65%
Technicals
SMA
Positive
20 days / 200 days
Momentum
60.92%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
24.27%
Trailing 12-Months
Company Description
Xeris Pharmaceuticals
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.
2B30 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong execution: substantial top-line growth (38% total revenue, 43% net product revenue), a near-doubling of Recorlev revenue (95% YoY), improved margins and profitability, and on-track pipeline progress with XP-8121 Phase III planned. Near-term headwinds were limited mainly to Gvoke (flat revenue) due to Medicare resets and increased near-term operating spend tied to deliberate commercial and R&D investments. Overall, positives (robust revenue growth, margin expansion, profitability, guidance raise and pipeline advancement) outweigh the operational and timing headwinds.View all DE:2B30 earnings summaries2B30 Stock 12 Month Forecast
Average Price Target
€10.77
▲(51.88% Upside)
Technical Analysis
Syndax Pharmaceuticals
―
Zymeworks
―
Arcus Biosciences
―
Stoke Therapeutics
―
Rapport Therapeutics, Inc.
―